Table
of Contents
|
|
|
|
|
|
Dedication |
v |
|
|
Acknowledgments |
xi |
|
|
About the Editor and Associate Editor |
xiii |
|
|
Contributing Authors |
xv |
|
|
Introduction |
xxi |
|
Prologue |
Historical
Perspective of Crohn's
Disease Wojciech Blonski, MD, PhD; David Kotlyar, MD;
Ming V. Lin, MD; and Gary R. Lkhtenstein, MD, FACP, FACG, AGAF |
1 |
|
SECTION I |
GENERAL |
9 |
|
Chapter 1 |
The Natural
History of Inflammatory Bowel Disease Pietro G. Andres, MD and Lawrence S. Friedman,
MD |
11 |
|
Chapter 2 |
Clinical
Research in Inflammatory Bowel Disease: Placebo Response in Clinical Trials Chinyu Su, MD and James D. Lewis, MD, MSCE |
25 |
|
Chapter 3 |
the Role of
the FDA in Drug Development in Inflammatory Bowel Disease Alan C. Moss, MD and Adam Cheifetz, MD |
31 |
|
Chapter 4 |
Utility of
Animal Models for the Study and Treatment of Inflammatory Bowel Disease Ashish Chawla, MD and Kenneth Simpson, BVM&S, PhD |
39 |
|
Chapter 5 |
Pediatric
Considerations in Medical Therapy in Patients with Inflammatory Bowel Disease Louis R. Ghanem, MD, PhD and Robert N. Daldassano, MD |
51 |
|
Chapter 6 |
the
Limitations of Applying Evidence-Based Medicine to Inflammatory Bowel
Disease: What We do Not Learn from
Clinical Trials Joshua R.
Korzenik, MD and
Corey A. Siegel, MD |
69 |
|
Chapter 7 |
Disease
Modifiers in Inflammatory Bowel Disease Jaime A.
Oviedo, MD and Francis A. Farraye, MD, Msc, FACP, FACG |
77 |
|
Chapter 8 |
Fertility
and Pregnancy in Inflammatory Bowel Disease Jeffrya. Katz, MD and Vinita Elizabeth Jacob, MD |
91 |
|
Chapter 9 |
Medication
Adherence in Inflammatory Bowel Disease Sunanda Kane, MD, MSPH, FACG, FACP, AGAF |
107 |
|
SECTION II |
MEDICATIONS |
113 |
|
Chapter 10 |
Mesalamine for Maintenance
Therapy in Ulcerative Colitis: How Much, How Long? Miles
P; Sparrow, MD, MBBS,
FRACP;
Wee-Chian
Him, MD, MBBS,
Mmed, MRCP; and
Stephen B. Hanauer, MD |
115 |
|
Chapter 11 |
Antibiotic
Use in the Treatment of Crohn's
Disease Manuel Mendizabal, MD; Wojciech Blonski, MD, PhD; David Kotlyar, MD; and
Gary R. Lichtenstein, MD, FACP, FACG, AGAF |
119 |
|
Chapter 12 |
Corticosteroids
in Crohn's
Disease Lene Riis, MD and Pia Munkholm, MD, Dmsci |
135 |
|
Chapter 13 |
Oral Budesonide for
Inflammatory Bowel Disease Gordon R.
Greenberg, MD, FRCP(C) |
143 |
|
Chapter 14 |
6-Mercaptopurine
and Azathioprine
in Crohn's
Disease Mark T, Osterman, MD and Gary R,
Lichtenstein, MD, FACP,
FACG, AGAF |
157 |
|
Chapter 15 |
Methotrexate in the Treatment
of Crohn's
Disease Ellen J.
Scherl, MD, FACP, AGAF; Arun Swaminath, MD;
Ryan Urquhart
Warren, MD; and Harrison Lakehomer,
BA |
177 |
|
Chapter 16 |
Calcineurin Inhibitors
(Cyclosporine A, Tacrolimus,
and Sirolimus)
and Mycophenolate Mofetil in Crohn's
Disease Gerassimos J.
Mantzaris, MD,
PhD, AGAF |
183 |
|
Chapter 17 |
Infliximab in Crohn's Disease Lawrence W. Comer Ford,
MD and Stephen J. Bickston, MD, AGAF |
197 |
|
Chapter 18 |
Anti-Tnfct Therapy
from Symptoms to Molecules: Impact of Individual
Variability on Anti-Tnfot
Optimization Strategies Ellen J.
Scherl, MD, FACP, AGAF |
213 |
|
Chapter 19 |
Novel
Biological Therapies for Crohn's
Disease Iris Dotan, MD and Daniel Rachmilewitz, MD |
225 |
|
Chapter 20 |
Novel Nonbiologic
Therapy for Crohn's
Disease Masayuki Fukata, MD, PhD and Maria T. Abreu, MD |
235 |
|
SECTION III |
SPECIFIC CLINICAL SCENARIOS |
249 |
|
Chapter 21 |
Assessment
of Disease Activity in Crohn's
Disease Alain Bitton, MD, FRCP(C) |
251 |
|
Chapter 22 |
General
Principles of Medical Therapy of Crohn's Disease Denis Franchimont, MD, PhD and Gary Wild,
MD |
267 |
|
Chapter 23 |
Medical
Management of Severe Crohn's
Disease |
283 |
|
Chapter 24 |
Medical
Management of Enteric Fistulae in Crohn's Disease Mamoon Raza, MD and Charles N. Bernstein, MD |
297 |
|
Chapter 25 |
Management
of Refractory Crohn's
Disease Herbert Tilg, MD and Arthur Kaser, MD |
305 |
|
Chapter 26 |
Medical
Management of Postoperative Recurrence of Crohn's Disease Geert D'Haens
MD, PhD and David N. Moskovitz, MD, FRCP(C) |
317 |
|
Chapter 27 |
Management
of Steroid-Unresponsive Crohn's
Disease Sarathchandra I, Reddy, MD, MPH and Robert Burakoff, MD,
MPH, FACG,
FACP |
329 |
|
Chapter 28 |
Pre- and Probiotics in Crohn's Disease Robert M. Penner, Bsc, MD, FRCP(C), Msc; Karen L. Madsen, PhD; and Richard N. Fedorak, MD, FRCP(C) |
341 |
|
Chapter 29 |
Management
of Crohn's
Disease in the Ileal-Pouch
Anal Anastomosis Gilaad G.
Kaplan MD, FRCP(C)
and Remo Panacclone MD, FRCP(C) |
345 |
|
Chapter 30 |
Dietary
Manipulations: Enteral
Therapy for Crohn's
Disease Alan L.
Buchman, MD, MSPH |
349 |
|
Chapter 31 |
Dietary
Manipulations: Parenteral
Therapy for Crohn's
Disease Alan L.
Buchman, MD, MSPH |
361 |
|
Chapter 32 |
Gastroduodenal/Proximal Crohn's Disease Ellen J. Scherl, MD, FACP, AGAF; Brian P. Bosworth, MD; Felice Schnoll-Sussman, MD; Douglas M. Weine, MD; and Peter H.
R. Green, MD |
369 |
|
Chapter 33 |
Medical
Management of Perianal
Fistula Tarun Misra, MD, FRCP(C) and Richard N. Fedorak, MD, FRCP(C) |
377 |
|
Chapter 34 |
Medical
Therapy of Diarrhea Following Bowel Resection Henry J. Binder, MD |
395 |
|
Chapter 35 |
Short Bowel
Syndrome Jane E.
Onken, MD, MHS |
405 |
|
Chapter 36 |
Medical
Management of the Patient with an Ostomy Aaron Brzezinski, MD, FRCP(C) |
417 |
|
Chapter 37 |
Maintenance
Therapy of Crohn's
Disease Wojciech
Blonski,
MD, PhD; Faten
Aberra,
MD, MSCE;
and Gary R. Lichtenstein, MD, FACP, FACG, AGAF |
425 |
|
Appendix |
Infliximab Treatment |
451 |
|
|
Financial Disclosures |
455 |
|
|
Index |
459 |
|
|
|
|